SELLAS Life Sciences (SLS) Assets Average (2011 - 2026)

SELLAS Life Sciences (SLS) has 16 years of Assets Average data on file, last reported at $96.3 million in Q1 2026.

• On a quarterly basis, Assets Average rose 253.98% year-over-year to $96.3 million in Q1 2026; TTM through Mar 2026 was $96.3 million, a 253.98% increase from a year earlier, with the FY2025 full-year figure at $48.9 million, up 281.18% from the prior year.
• Assets Average for Q1 2026 stood at $96.3 million, up from $65.0 million in the prior quarter.
• Over the last five years, Assets Average for SLS reached as high as $96.3 million in Q1 2026 and fell as low as $7.2 million in Q4 2023.
• Historically, Assets Average has averaged $30.3 million across 5 years, with a median of $23.9 million in 2022.
• Across the five-year window, Assets Average slumped 69.53% in 2023 and soared 253.98% in 2026, its largest moves.
• Year by year, Assets Average stood at $23.5 million in 2022, then slumped by 69.53% to $7.2 million in 2023, then jumped by 221.13% to $23.0 million in 2024, then jumped by 182.78% to $65.0 million in 2025, then soared by 48.21% to $96.3 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $96.3 million in Q1 2026, $65.0 million in Q4 2025, and $41.9 million in Q3 2025.